• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The clinical characteristics of 80 cases of acquired immunodeficiency syndrome-associated Kaposi's sarcoma in Xinjiang Autonomous Region and the effect of different treatments on the prognosis.新疆地区80例获得性免疫缺陷综合征相关卡波西肉瘤的临床特征及不同治疗方法对预后的影响
Int J Clin Exp Med. 2015 Oct 15;8(10):18697-704. eCollection 2015.
2
Risk factors for Kaposi's sarcoma in human immunodeficiency virus patients after initiation of antiretroviral therapy: A nested case-control study in Kenya.抗逆转录病毒治疗后开始后人类免疫缺陷病毒患者卡波西肉瘤的风险因素:肯尼亚的一项嵌套病例对照研究。
J Microbiol Immunol Infect. 2017 Dec;50(6):781-788. doi: 10.1016/j.jmii.2015.10.009. Epub 2015 Dec 2.
3
A retrospective study of Kaposi's sarcoma in Hotan region of Xinjiang, China.中国新疆和田地区卡波西肉瘤的回顾性研究。
Medicine (Baltimore). 2023 Oct 13;102(41):e35552. doi: 10.1097/MD.0000000000035552.
4
Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.卡波西肉瘤相关疱疹病毒特异性免疫重建以及高效抗逆转录病毒治疗/化疗联合方案对感染C型HIV且患有卡波西肉瘤个体的抗病毒作用
AIDS. 2007 Jun 19;21(10):1245-52. doi: 10.1097/QAD.0b013e328182df03.
5
Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome.高效抗逆转录病毒治疗(HAART)开始后复发的卡波西肉瘤:免疫重建综合征的一种表现
AIDS Patient Care STDS. 2005 Oct;19(10):635-44. doi: 10.1089/apc.2005.19.635.
6
A Retrospective Study on Changing Trends of Acquired Immunodeficiency Syndrome related Kaposi's Sarcoma in North-Western Nigeria.尼日利亚西北部获得性免疫缺陷综合征相关卡波西肉瘤变化趋势的回顾性研究。
West Afr J Med. 2022 Jul 31;39(7):663-669.
7
Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma.与卡波西肉瘤相关的免疫重建炎症综合征
J Clin Oncol. 2005 Aug 1;23(22):5224-8. doi: 10.1200/JCO.2005.14.597.
8
Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy.预测艾滋病相关卡波西肉瘤对高效抗逆转录病毒疗法临床反应的病毒学和免疫学参数。
J Invest Dermatol. 2001 Oct;117(4):858-63. doi: 10.1046/j.0022-202x.2001.01465.x.
9
AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.艾滋病相关卡波西肉瘤:在高效抗逆转录病毒治疗时代评估潜在的新预后因素及艾滋病临床试验组分期系统——意大利艾滋病与肿瘤合作组及意大利未接受过抗逆转录病毒治疗患者队列
J Clin Oncol. 2003 Aug 1;21(15):2876-82. doi: 10.1200/JCO.2003.10.162.
10
Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.高效抗逆转录病毒治疗时代卡波西肉瘤患者的特征
J Clin Oncol. 2005 Feb 20;23(6):1253-60. doi: 10.1200/JCO.2005.04.156.

本文引用的文献

1
Risk factors for Kaposi's sarcoma among HIV-positive individuals in a case control study in Cameroon.喀麦隆一项病例对照研究中HIV阳性个体患卡波西肉瘤的风险因素。
Cancer Epidemiol. 2014 Apr;38(2):137-43. doi: 10.1016/j.canep.2014.02.006. Epub 2014 Mar 13.
2
Successful treatment of an HIV-positive patient with unmasking Kaposi's sarcoma immune reconstitution inflammatory syndrome.成功治疗一名 HIV 阳性患者的卡波西肉瘤免疫重建炎症综合征。
J Clin Virol. 2013 Jul;57(3):282-5. doi: 10.1016/j.jcv.2013.03.005. Epub 2013 Apr 8.
3
Oral HIV-associated Kaposi sarcoma.口腔艾滋病相关性卡波西肉瘤。
J Oral Pathol Med. 2013 Mar;42(3):201-7. doi: 10.1111/j.1600-0714.2012.01180.x. Epub 2012 Jun 5.
4
Immune reconstitution inflammatory syndrome of Kaposi's sarcoma in an HIV-infected patient.艾滋病患者卡波西肉瘤免疫重建炎症综合征。
J Microbiol Immunol Infect. 2013 Aug;46(4):309-12. doi: 10.1016/j.jmii.2012.01.006. Epub 2012 Apr 12.
5
A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.南非未经治疗的 HIV 相关性卡波西肉瘤患者中高效抗逆转录病毒治疗与高效抗逆转录病毒治疗联合化疗的随机对照试验。
J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):150-7. doi: 10.1097/QAI.0b013e318251aedd.
6
A fatal case of kaposi sarcoma due to immune reconstitution inflammatory syndrome.因免疫重建炎症综合征导致的卡波西肉瘤致死病例。
Am J Med Sci. 2012 May;343(5):421-5. doi: 10.1097/MAJ.0b013e31823eff35.
7
[Clinical manifestation of HIV infection and AIDS in otorhinolaryngology head and neck surgery].[耳鼻咽喉头颈外科中HIV感染与艾滋病的临床表现]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Mar;46(3):232-4.
8
[Opportunistic infections in HIV/AIDS].[人类免疫缺陷病毒/获得性免疫缺陷综合征中的机会性感染]
Nihon Rinsho. 2010 Mar;68(3):486-90.
9
Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome.高效抗逆转录病毒治疗(HAART)开始后复发的卡波西肉瘤:免疫重建综合征的一种表现
AIDS Patient Care STDS. 2005 Oct;19(10):635-44. doi: 10.1089/apc.2005.19.635.
10
Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.高效抗逆转录病毒治疗期间艾滋病相关卡波西肉瘤的长期临床结局
Int J Oncol. 2005 Sep;27(3):779-85.

新疆地区80例获得性免疫缺陷综合征相关卡波西肉瘤的临床特征及不同治疗方法对预后的影响

The clinical characteristics of 80 cases of acquired immunodeficiency syndrome-associated Kaposi's sarcoma in Xinjiang Autonomous Region and the effect of different treatments on the prognosis.

作者信息

Yang Tongtong, He Li, Wan Xuefeng, Maimaitiaili Wubuli, Song Yuxia, Zhang Yuexin, Lu Xiaobo

机构信息

Department of Infectious Diseases, Sixth People's Hospital of Xinjiang Urumqi, P. R. China.

Department of Infectious Diseases, The First Teaching Hospital of Xinjiang Medical University Urumqi, P. R. China.

出版信息

Int J Clin Exp Med. 2015 Oct 15;8(10):18697-704. eCollection 2015.

PMID:26770484
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4694384/
Abstract

To analyze the clinical features of AIDS-related Kaposi's sarcoma (AIDS-KS) patients in Xinjiang Autonomous Region and the impact of CD4 (+)T lymphocyte count, highly active antiretroviral therapy (HAART) and systemic chemotherapy on the prognosis. The clinical information of 80 AIDS-KS patients admitted in Sixth People's Hospital of Xinjiang Autonomous Region from January 2008 to August 2014 was retrospectively reviewed. Population characteristics, extent of lesions, KS progress, CD4 (+)T lymphocyte count, combined opportunistic infections, treatment and prognosis of these patients were analyzed. The 80 patients were divided into five groups according to treatment methods, including HAART, HAART + chemotherapy, chemotherapy + HAART, chemotherapy, and untreated groups. The efficacy and prognosis of the five groups were compared. Among the 80 patients, 74 (92.50%) patients were Uygur. The average age was 39.5±9.9 years and male-to-female ratio was 3:1. The median of baseline CD4 (+)T lymphocyte count was 152.5 cells/μL and the interquartile was 233.25 cells/μL. CD4 (+)T lymphocyte counts were significantly increased after treatment in HAART, HAART + chemotherapy, and chemotherapy + HAART groups (P < 0.05). CD4 (+)T lymphocyte count in chemotherapy groups was significantly reduced after treatment (P < 0.05). The untreated group had the highest mortality rate (33.3%). In HAART group, KS-associated immune reconstitution inflammatory response syndrome (KS-IRIS) appeared in 45.5% cases and 2 death cases were caused by KS-IRIS. In Xinjiang Autonomous Region, the incidence of AIDS-KS is high in young Uygur male people. HAART followed by chemotherapy has ideal efficacy, reduces the incidence of KS-IRIS and improves the prognosis.

摘要

分析新疆地区艾滋病相关卡波西肉瘤(AIDS-KS)患者的临床特征以及CD4(+)T淋巴细胞计数、高效抗逆转录病毒治疗(HAART)和全身化疗对预后的影响。回顾性分析2008年1月至2014年8月在新疆维吾尔自治区第六人民医院收治的80例AIDS-KS患者的临床资料。分析这些患者的人口学特征、病变范围、KS进展情况、CD4(+)T淋巴细胞计数、合并机会性感染情况、治疗方法及预后。根据治疗方法将80例患者分为五组,包括HAART组、HAART+化疗组、化疗+HAART组、化疗组和未治疗组。比较五组的疗效及预后。80例患者中,维吾尔族74例(92.50%)。平均年龄39.5±9.9岁,男女比例为3∶1。基线CD4(+)T淋巴细胞计数中位数为152.5个/μL,四分位数间距为233.25个/μL。HAART组、HAART+化疗组和化疗+HAART组治疗后CD4(+)T淋巴细胞计数显著升高(P<0.05)。化疗组治疗后CD4(+)T淋巴细胞计数显著降低(P<0.05)。未治疗组死亡率最高(33.3%)。HAART组中,45.5%的病例出现KS相关免疫重建炎症反应综合征(KS-IRIS),2例死亡病例由KS-IRIS导致。在新疆地区,年轻维吾尔族男性AIDS-KS发病率高。HAART序贯化疗疗效理想,可降低KS-IRIS发生率,改善预后。